TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02806141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized plus intravenous colistin
Description: Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous colistin
Description: Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
Study: NCT02024789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally twice daily, 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: 120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: 240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Study: NCT01208363

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Cowpea fortified with NaFeEDTA, in form of Toubani.
Description: 66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
Study: NCT03407365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Week Exercise Program
Description: Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD Program After 10 Weeks
Description: If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
Study: NCT03189888

Intervention type: DEVICE
Group type: OTHER
Intervention: apheresis
Study: NCT02924038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA950
Description: IMA950 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA950
Description: IMA950 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly-ICLC
Description: poly-ICLC vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly-ICLC
Description: poly-ICLC vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Intravenous solution
Study: NCT04063358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.5 MG Per 0.05 ML Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis 0.5 MG Per 0.05 ML Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.5 MG Per 0.05 ML Injection
Study: NCT01888081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1) (Resimmune®)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ionizing Radiation
Study: NCT01320696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Description: Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
Description: Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
Study: NCT00822926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
Study: NCT04995393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heating with a gel pack
Description: Heating of the infants heel with a gel pack before blood sampling.
Study: NCT00540254

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care for Chronic Fatigue Syndrome (Active Control Group)
Description: Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
Study: NCT02991092

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fluid administration
Description: After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid administration
Description: After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered.
Study: NCT00690144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
Description: Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
Study: NCT03050411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: 250mg, 500mg, 750mg, q.d., p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
Study: NCT01282580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza-Omega 3 fatty acid capsules
Description: The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fish (canned salmon, albacore)
Description: Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
Study: NCT01962324

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB Dose-Escalation Radiotherapy
Study: NCT04423198

Intervention type: BEHAVIORAL
Intervention: Cognitive Assessment
Description: Self administered cognitive battery

Intervention type: BEHAVIORAL
Intervention: Cognitive Assessment
Description: Self administered cognitive battery

Intervention type: BEHAVIORAL
Intervention: Cognitive Assessment
Description: Self administered cognitive battery

Intervention type: BEHAVIORAL
Intervention: Patient Reported Neurological Outcome Assessments
Description: Standard neurocognitive and neuropsychological tests

Intervention type: BEHAVIORAL
Intervention: Patient Reported Neurological Outcome Assessments
Description: Standard neurocognitive and neuropsychological tests

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Specimen collection of whole blood, serum, RNA

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Specimen collection of whole blood, serum, RNA

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Specimen collection of whole blood, serum, RNA
Study: NCT03332849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: HM12470 is a long-acting insulin analogue
Study: NCT00859456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs).
Study: NCT04237142

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal secretions collection
Description: Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
Study: NCT01300013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 48-hour infusion of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: 48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
Study: NCT03395236

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon
Description: The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency.
Study: NCT03708783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection
Description: For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
Study: NCT01868542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
Study: NCT03007641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic session
Description: This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
Study: NCT00202475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: eythrocytapheresis
Description: machinal collection of erythrocytes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: whole blood collection
Description: collection of whole blood
Study: NCT01317459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-determination
Description: Group counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-determination
Description: Group counselling
Study: NCT03730792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIFT Onboard Intervention
Description: A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
Study: NCT04299932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
Study: NCT01124864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
Study: NCT03093662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation with nasal cannula
Description: Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation with nasal cannula
Description: Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation without nasal cannula
Description: Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation without nasal cannula
Description: Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
Study: NCT03933891

Intervention type: PROCEDURE
Intervention: TIPS
Description: TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
Study: NCT04099264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music
Description: Patients in the intervention group will listen to personalized music from the Musicare application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio Books
Description: Patients in the active comparator group will listen to audio books
Study: NCT02682862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg
Description: Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol 2.5 mcg
Description: Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
Study: NCT02803346

Intervention type: OTHER
Intervention: Circulating blood (leukocytes)
Description: mHLA-DR measurement (in vitro)
Study: NCT01934270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anaerobic Test
Description: To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
Study: NCT02817425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX Sequential S-1
Description: 8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX
Description: S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEGAFOX Sequential S-1.
Description: 6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
Study: NCT01037764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alloHCT
Description: \[ alloHCT arm \] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg\*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg\* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg\*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1.
Study: NCT00973817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD plus standard of care treatment
Description: Use of ELAD plus standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care in the treatment of AOCH will be administered

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care in the treatment of AOCH will be administered
Study: NCT02611596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 24 weeks of the assigned medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 24 weeks
Study: NCT03314571

Intervention type: OTHER
Intervention: analgesia for labor
Description: A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
Study: NCT01976598

Intervention type: OTHER
Intervention: Sub-Sensory Stimulation
Description: Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
Study: NCT02645175

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TW1025
Description: 20ml, 3 times per day (daily dose: 60 ml)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20ml, 3 times per day (daily dose: 60 ml)